Association Study of Transforming Growth Factor Beta 1 + 29 T/C Exon 1 Polymorphism in Breast Cancer Patients from North Indian Population

Overview

Journal Appl Biochem Biotechnol

Specialties Biochemistry
Biotechnology

Date 2023 Mar 23

PMID 36951937

Authors

Ranjana Pal

Siddhartha Dutta

Affiliations

Soon will be listed here.

Abstract

Background: TGFB1 cytokine is involved in normal mammary epithelial development as well as in breast tumorigenesis. It has role in both breast tumor suppression and progression. TGFB1 gene has several single nucleotide polymorphisms (SNPs) many of which modulate the activity of TGFB1. Our aim in this study was to analyze TGFB1 + 29 polymorphism in breast cancer individuals from North Indian population.

Methods: TGFB1 + 29 T/C polymorphism was analyzed using Sanger sequencing in 285 breast cancer patients and age matched 363 healthy controls from North Indian population. Next, transcript expression of 13 apoptotic genes, TRAIL, DR4, DR5, DcR1, DcR2, Bcl2, cytochrome c, Casp8L, Casp8, FlipS, FlipL, Casp3s and Casp3 were carried out in 77 breast tumor tissues obtained from 77 individuals.

Results: TGFB1 + 29 CC genotype provided protection against the development of breast cancer (P = 0.012). This was mainly attributable to higher age group (> 45 years) women (P = 0.016). Individuals having CC protector genotype showed significantly higher expression of TGFB1 transcript compared to the TT and TC risk genotypes (P = 0.044). Furthermore, we observed that TGFB1 + 29 CC genotype showed increased TRAIL mediated apoptosis via the extrinsic pathway in breast tumor patients with age greater than 45 years (P = 0.027).

Conclusion: TGFB1 + 29 homozygous mutant CC genotype is related to protection against breast cancer in North Indian women population greater than 45 years of age.

References

Dranoff G . Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004; 4(1):11-22. DOI: 10.1038/nrc1252. View

Xu X, Zheng L, Yuan Q, Zhen G, Crane J, Zhou X . Transforming growth factor-β in stem cells and tissue homeostasis. Bone Res. 2018; 6:2. PMC: 5802812. DOI: 10.1038/s41413-017-0005-4. View

Goumans M, Liu Z, Ten Dijke P . TGF-beta signaling in vascular biology and dysfunction. Cell Res. 2008; 19(1):116-27. DOI: 10.1038/cr.2008.326. View

Massague J . TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012; 13(10):616-30. PMC: 4027049. DOI: 10.1038/nrm3434. View

Roberts A, Wakefield L . The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A. 2003; 100(15):8621-3. PMC: 166359. DOI: 10.1073/pnas.1633291100. View

Ahn Y, Lee J, Sung M, Heo D . Presence of membrane-bound TGF-beta1 and its regulation by IL-2-activated immune cell-derived IFN-gamma in head and neck squamous cell carcinoma cell lines. J Immunol. 2009; 182(10):6114-20. DOI: 10.4049/jimmunol.0803725. View

Khoshakhlagh M, Soleimani A, Moradi Binabaj M, Avan A, Ferns G, Khazaei M . Therapeutic potential of pharmacological TGF-β signaling pathway inhibitors in the pathogenesis of breast cancer. Biochem Pharmacol. 2019; 164:17-22. DOI: 10.1016/j.bcp.2019.03.031. View

Moore-Smith L, Isayeva T, Lee J, Frost A, Ponnazhagan S . Silencing of TGF-β1 in tumor cells impacts MMP-9 in tumor microenvironment. Sci Rep. 2017; 7(1):8678. PMC: 5561077. DOI: 10.1038/s41598-017-09062-y. View

Falschlehner C, Emmerich C, Gerlach B, Walczak H . TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol. 2007; 39(7-8):1462-75. DOI: 10.1016/j.biocel.2007.02.007. View

10.

Johnstone R, Frew A, Smyth M . The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008; 8(10):782-98. DOI: 10.1038/nrc2465. View

11.

Ashkenazi A . Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 2008; 7(12):1001-12. DOI: 10.1038/nrd2637. View

12.

Vegran F, Boidot R, Oudin C, Riedinger J, Bonnetain F, Lizard-Nacol S . Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res. 2006; 12(19):5794-800. DOI: 10.1158/1078-0432.CCR-06-0725. View

13.

Herzer K, Ganten T, Schulze-Bergkamen H, Grosse-Wilde A, Koschny R, Krammer P . Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cells. Hepatology. 2005; 42(1):183-92. DOI: 10.1002/hep.20757. View

14.

Sanchez-Capelo A . Dual role for TGF-beta1 in apoptosis. Cytokine Growth Factor Rev. 2005; 16(1):15-34. DOI: 10.1016/j.cytogfr.2004.11.002. View

15.

Saltzman A, Munro R, Searfoss G, Franks C, Jaye M, Ivashchenko Y . Transforming growth factor-beta-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res. 1998; 242(1):244-54. DOI: 10.1006/excr.1998.4096. View

16.

Shima Y, Nakao K, Nakashima T, Kawakami A, Nakata K, Hamasaki K . Activation of caspase-8 in transforming growth factor-beta-induced apoptosis of human hepatoma cells. Hepatology. 1999; 30(5):1215-22. DOI: 10.1002/hep.510300503. View

17.

Cao Y, Chen L, Zhang W, Liu Y, Papaconstantinou H, Bush C . Identification of apoptotic genes mediating TGF-beta/Smad3-induced cell death in intestinal epithelial cells using a genomic approach. Am J Physiol Gastrointest Liver Physiol. 2006; 292(1):G28-38. DOI: 10.1152/ajpgi.00437.2005. View

18.

Lafon C, Mathieu C, Guerrin M, Pierre O, Vidal S, Valette A . Transforming growth factor beta 1-induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N-acetylcysteine and bcl-2. Cell Growth Differ. 1996; 7(8):1095-104. View

19.

Cano-Gonzalez A, Lopez-Rivas A . Opposing roles of TGF-β and EGF in the regulation of TRAIL-induced apoptosis in human breast epithelial cells. Biochim Biophys Acta. 2016; 1863(8):2104-14. DOI: 10.1016/j.bbamcr.2016.05.011. View

20.

Bedi A, Chang X, Noonan K, Pham V, Bedi R, Fertig E . Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol Cancer Ther. 2012; 11(11):2429-39. PMC: 3640459. DOI: 10.1158/1535-7163.MCT-12-0101-T. View